Peptide and protein drug delivery to and into tumors: challenges and solutions.

[1]  Eric Vives,et al.  Cell-penetrating Peptides , 2003, The Journal of Biological Chemistry.

[2]  D. Wyss,et al.  Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. , 2002, Current pharmaceutical design.

[3]  Y. Tseng,et al.  Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. , 2002, Molecular pharmacology.

[4]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[5]  M. Gore,et al.  Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Dowdy,et al.  c-Rel regulation of the cell cycle in primary mouse B lymphocytes. , 2002, International immunology.

[7]  W. Jiskoot,et al.  Functional Characterization of an Endosome-disruptive Peptide and Its Application in Cytosolic Delivery of Immunoliposome-entrapped Proteins* , 2002, The Journal of Biological Chemistry.

[8]  A. Hoffman,et al.  A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex. , 2002, Bioconjugate chemistry.

[9]  Veronese Fm,et al.  Introduction and overview of peptide and protein pegylation. , 2002 .

[10]  M. Bentley,et al.  Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.

[11]  I. Smith,et al.  The development and clinical use of trastuzumab (Herceptin). , 2002, Endocrine-related cancer.

[12]  W. Figg,et al.  Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer , 2002, Investigational New Drugs.

[13]  Francis C Szoka,et al.  Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. , 2002, Bioconjugate chemistry.

[14]  B. Wang,et al.  Recent developments in depsipeptide research. , 2002, Current medicinal chemistry.

[15]  S. Hussain,et al.  Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. , 2001, Lung cancer.

[16]  Allan Balmain,et al.  Cancer genetics: from Boveri and Mendel to microarrays , 2001, Nature Reviews Cancer.

[17]  K. Hruska,et al.  Rho family GTPases regulate VEGF-stimulated endothelial cell motility. , 2001, Experimental cell research.

[18]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[19]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[20]  V. Torchilin,et al.  TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Workman.  New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. , 2001, Current cancer drug targets.

[22]  H. Marshall.  20% of sufferers could outgrow peanut allergy. , 2001, Trends in immunology.

[23]  H. Marshall.  Anti-CD20 antibody therapy is highly effective in the treatment of follicular lymphoma. , 2001, Trends in immunology.

[24]  Y. Reiter,et al.  Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins. , 2001, Current pharmaceutical biotechnology.

[25]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[26]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[27]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[28]  M. Chao,et al.  p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal , 2001, EMBO reports.

[29]  R. Dillman,et al.  Monoclonal Antibodies in the Treatment of Malignancy: Basic Concepts and Recent Developments , 2001, Cancer investigation.

[30]  S. Hussain,et al.  p53 Tumor Suppressor Gene: At the Crossroads of Molecular Carcinogenesis, Molecular Epidemiology, and Human Risk Assessment , 2000, Annals of the New York Academy of Sciences.

[31]  R Weissleder,et al.  Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-tat derived membrane translocation peptide. , 2000, Bioconjugate chemistry.

[32]  Ralph Weissleder,et al.  Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells , 2000, Nature Biotechnology.

[33]  J. Gibbs.  Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.

[34]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[35]  Wagner.  Application of membrane-active peptides for nonviral gene delivery. , 1999, Advanced drug delivery reviews.

[36]  S. Dowdy,et al.  Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. , 1999, Cancer research.

[37]  Y. Tsutsumi,et al.  Bioconjugation of laminin peptide YIGSR with poly(styrene co-maleic acid) increases its antimetastatic effect on lung metastasis of B16-BL6 melanoma cells. , 1999, Biochemical and biophysical research communications.

[38]  M. Cima,et al.  A controlled-release microchip , 1999, Nature.

[39]  Vladimir P. Torchilin,et al.  Accumulation of Protein-Loaded Long-Circulating Micelles and Liposomes in Subcutaneous Lewis Lung Carcinoma in Mice , 1998, Pharmaceutical Research.

[40]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[41]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Monsigny,et al.  Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. , 1998, Bioconjugate chemistry.

[43]  R. Egleton,et al.  Bioavailability and Transport of Peptides and Peptide Drugs into the Brain , 1997, Peptides.

[44]  Priscille Brodin,et al.  A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus* , 1997, The Journal of Biological Chemistry.

[45]  L. Holle.  Pegaspargase: An Alternative? , 1997, The Annals of pharmacotherapy.

[46]  G. Elliott,et al.  Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein , 1997, Cell.

[47]  R. Cortese.  Combinatorial libraries : synthesis, screening and application potential , 1996 .

[48]  V. Torchilin,et al.  Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .

[49]  Vladimir P. Torchilin,et al.  Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents , 1995 .

[50]  V. Torchilin,et al.  Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. , 1995, Immunology letters.

[51]  J. Gibbs,et al.  Pharmaceutical research in molecular oncology , 1994, Cell.

[52]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[53]  A. Prochiantz,et al.  The third helix of the Antennapedia homeodomain translocates through biological membranes. , 1994, The Journal of biological chemistry.

[54]  H. Kamata,et al.  Amphiphilic peptides enhance the efficiency of liposome-mediated DNA transfection. , 1994, Nucleic acids research.

[55]  H. Buchwald,et al.  Implantable pumps. Recent progress and anticipated future advances. , 1992, ASAIO journal.

[56]  A. Frankel,et al.  Endocytosis and targeting of exogenous HIV‐1 Tat protein. , 1991, The EMBO journal.

[57]  H. Maeda,et al.  SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.

[58]  Ph.D. Dr. Sci. Vladimir P. Torchilin.  Immobilized Enzymes in Medicine , 1991, Progress in Clinical Biochemistry and Medicine.

[59]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[60]  M. Hashida,et al.  Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties. , 1989, Journal of pharmaceutical sciences.

[61]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[62]  C. Verhoest,et al.  Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. , 1984, Cancer biochemistry biophysics.

[63]  J. Uhr,et al.  Immunotoxins: a new approach to cancer therapy. , 1983, Science.

[64]  G. Gregoriadis.  Targeting of drugs , 1977, Nature.

[65]  A. Eberle,et al.  Somatostatin analogs and radiopeptides in cancer therapy. , 2002, Biopolymers.

[66]  Robert Langer,et al.  Moving smaller in drug discovery and delivery , 2002, Nature Reviews Drug Discovery.

[67]  J. Baselga,et al.  Mechanism of action of anti-HER2 monoclonal antibodies. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  J. M. Harris,et al.  Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.

[69]  G. Waksman,et al.  Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. , 2001, Cancer research.

[70]  S. Dowdy,et al.  Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. , 2000, Methods in enzymology.

[71]  B. Asselin.  The Three Asparaginases , 1999 .

[72]  B. Asselin,et al.  The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. , 1999, Advances in experimental medicine and biology.

[73]  V. Torchilin,et al.  Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. , 1998, Cancer detection and prevention.

[74]  D. Papahadjopoulos,et al.  Medical applications of liposomes , 1998 .

[75]  T K Sawyer,et al.  Src homology‐2 domains: Structure, mechanisms, and drug discovery , 1998, Biopolymers.

[76]  B. Katz.  Structural and mechanistic determinants of affinity and specificity of ligands discovered or engineered by phage display. , 1997, Annual review of biophysics and biomolecular structure.

[77]  Torchilin Vp,et al.  A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. , 1997 .

[78]  V. Torchilin.  Handbook of targeted delivery of imaging agents , 1995 .

[79]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1993, Cancer chemotherapy and biological response modifiers.

[80]  J H Senior,et al.  Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.